Colorectal Cancer Trial, Recruiting NCT04927897 Sponsor: Maastricht Radiation Oncology Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT04927897
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older and are able to understand and agree to participate in the trial.
  • People who have been diagnosed with rectal cancer (a type of cancer called adenocarcinoma) that has been confirmed by examination or scans, has not spread to nearby lymph nodes, and still has some cancer remaining after receiving radiation therapy or a combination of chemotherapy and radiation therapy — and who are scheduled to have a specific type of bowel surgery called TME (total mesorectal excision).
  • People whose cancer has come back after an earlier period where no cancer could be detected (sometimes called "watch and wait") are also eligible, as long as the return of cancer has been confirmed by camera examination of the bowel and/or a scan.
  • At least 6 weeks must have passed between the end of radiation or chemoradiation treatment and the planned surgery.

Who may not be able to join:

  • People who received a type of internal radiation treatment called brachytherapy as part of their cancer treatment before surgery.
  • People under 18 years of age, or those who are unable to give informed consent.
  • People who did not receive radiation therapy or combined chemotherapy and radiation therapy before surgery.
  • People who are not scheduled to have TME surgery for the confirmed type and stage of rectal cancer described above.
  • People for whom fewer than 6 weeks have passed between finishing neoadjuvant treatment and the planned surgery date.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maaike Berbée, MD, PhD, Maastro

Phone: 0031884455600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Maastricht Radiation Oncology
Registry
ClinicalTrials.gov
Start date
16 August 2022
Est. completion
1 May 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov